Institute for Health-Economics & Health-Care Research, University of Applied Sciences, Cologne, Department of Internal Medicine, Heidelberg University Hospital at the Ruprecht-Karls-University, Cardiology and Angiology Center, Cologne, pronova BKK, Statutory Health Insurance, Cologne, Department of Cardiology, St. Marien-Hospital Hamm (teaching hospital of the University of Münster), Department of Cardiology, Angiology and Diabetology, Cologne-Merheim Hospital, Kliniken der Stadt Köln, Cologne.
Dtsch Arztebl Int. 2014 Apr 11;111(15):264-70. doi: 10.3238/arztebl.2014.0264.
At 360 000 cases annually, heart failure is the most common main diagnosis in adults in German hospitals. Treating heart failure is expensive. This study tested whether patients in the case management program (CMP) "CorBene--Better Care for Patients With Heart Failure" have a lower mortality rate and lower hospital admission and readmission rates than patients receiving regular management.
Routine data from a large German statutory health insurance company were analyzed. After propensity score matching, a total of 1202 patients (intervention group versus control group) were studied in relation to the endpoint "hospital admission and readmission rate" and the variables "annual physician contact rate," "mortality," and "inpatient treatment costs."
The intervention group showed a lower rate of hospital admission/readmission (6.2%/18.9% versus 16.6%/36.0%; p<0.0001 / p = 0.041). Mortality rates did not differ significantly (5.0% versus 6.7%; p = 0.217). Analysis of hospital admission data showed no significant differences between the groups in terms of length of hospital stay or costs for heart failure-related treatment per hospital stay. However, the average annual costs for inpatient treatment in the CMP group, at €222.22 per patient, were 67.5% lower than the equivalent costs in the control group (€683.88) (p<0.0001).
Fewer patients in the intervention group were admitted and readmitted to hospital, and lower inpatient treatment costs were identified. The physician contact rate was higher than in the control group.
在德国医院,心力衰竭是成人中最常见的主要诊断,每年有 360,000 例。治疗心力衰竭的费用很高。本研究测试了心力衰竭病例管理计划(CMP)“CorBene-改善心力衰竭患者的护理”中的患者是否比接受常规管理的患者死亡率更低,住院和再入院率更低。
分析了一家大型德国法定健康保险公司的常规数据。经过倾向评分匹配后,共有 1202 名患者(干预组与对照组)在终点“住院和再入院率”以及变量“每年医生接触率”、“死亡率”和“住院治疗费用”方面进行了研究。
干预组的住院/再入院率较低(6.2%/18.9%对 16.6%/36.0%;p<0.0001 / p = 0.041)。死亡率无显著差异(5.0%对 6.7%;p = 0.217)。对住院数据的分析显示,两组在住院时间长短或心力衰竭相关治疗每住院时间的费用方面无显著差异。然而,CMP 组的平均住院治疗年度费用为每位患者 222.22 欧元,比对照组(683.88 欧元)低 67.5%(p<0.0001)。
干预组的患者住院和再入院人数减少,住院治疗费用降低。医生的接触率高于对照组。